Bulletin
Investor Alert

Century Therapeutics Inc.

NAS: IPSC

GO

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders
/marketstate/country/us
Century Therapeutics Inc.

After Hours

 --Quotes are delayed by 20 min

Mar 24, 2023, 4:57 p.m.

IPSC
/zigman2/quotes/210490648/composite

$

3.65

Change

0.00 0.00%

Volume

Volume 4,268

Quotes are delayed by 20 min

/zigman2/quotes/210490648/composite

Previous close

$ 3.49

$ 3.65

Change

+0.16 +4.58%

Day low

Day high

$3.40

$3.69

Open

52 week low

52 week high

$3.40

$14.00

Open

Company Description

Century Therapeutics, Inc. engages in the development of off-the-shelf cell therapies to advance the course of cancer care. It engages in harnessing the power of adult stem cells to develop curative allogeneic cell therapies for cancer. The company was founded by Marcela Maus and Hiromitsu Nakauchi ...

Century Therapeutics, Inc. engages in the development of off-the-shelf cell therapies to advance the course of cancer care. It engages in harnessing the power of adult stem cells to develop curative allogeneic cell therapies for cancer. The company was founded by Marcela Maus and Hiromitsu Nakauchi in 2018 and is headquartered in Philadelphia, PA.

Valuation

Price to Sales Ratio

56.99

Price to Book Ratio

0.99

Price to Cash Flow Ratio

35.73

Enterprise Value to EBITDA

0.52

Enterprise Value to Sales

-11.46

Total Debt to Enterprise Value

1.64

Efficiency

Revenue/Employee

31,896.00

Income Per Employee

-803,264.00

Receivables Turnover

10.10

Total Asset Turnover

0.01

Liquidity

Current Ratio

10.72

Quick Ratio

10.72

Cash Ratio

10.58

Profitability

Gross Margin

-93.71

Operating Margin

-2,381.82

Pretax Margin

-2,516.66

Net Margin

-2,518.41

Return on Assets

-28.34

Return on Equity

-37.46

Return on Total Capital

-32.02

Return on Invested Capital

-34.24

Capital Structure

Total Debt to Total Equity

16.32

Total Debt to Total Capital

14.03

Total Debt to Total Assets

10.16

Long-Term Debt to Equity

14.02

Long-Term Debt to Total Capital

12.05

Officers and Executives

Name Age Officer Since Title
Mr. Joseph Jimenez 60 2019 Director
Dr. Osvaldo Flores - - Chief Executive Officer & Director
Dr. Adrienne Farid 59 2021 Chief Operations Officer

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
02/02/2023 Douglas Carr
VP Finance & Operations 		7,500   Award at $0 per share. 0
02/02/2023 Douglas Carr
VP Finance & Operations 		7,500   Award at $0 per share. 0
02/02/2023 Mike C. Diem
Chief Business Officer 		21,875   Award at $0 per share. 0
02/02/2023 Mike C. Diem
Chief Business Officer 		21,875   Award at $0 per share. 0
02/02/2023 Adrienne Farid
Chief Operations Officer 		21,875   Award at $0 per share. 0
02/02/2023 Adrienne Farid
Chief Operations Officer 		21,875   Award at $0 per share. 0
02/02/2023 Luis Borges
Chief Scientific Officer 		21,875   Award at $0 per share. 0
02/02/2023 Luis Borges
Chief Scientific Officer 		21,875   Award at $0 per share. 0
08/09/2022 Versant Venture Management LLC
364,800   0
08/09/2022 Versant Venture Management LLC
550,000   Disposition at $13.03 per share. 7,166,500
01/31/2022 Versant Venture Management LLC
178,996   0
12/23/2021 Versant Venture Management LLC
371,004   0
06/22/2021 Bayer AG
750,000   Acquisition at $20 per share. 15,000,000
06/22/2021 Versant Venture Management LLC
100,000   Acquisition at $20 per share. 2,000,000
06/22/2021 Eli Casdin
Director 		750,000   Acquisition at $20 per share. 15,000,000
06/22/2021 Bayer AG
1,535,238   Derivative/Non-derivative trans. at $0 per share. 0
06/22/2021 Bayer AG
10,390,600   Derivative/Non-derivative trans. at $0 per share. 0
06/22/2021 Versant Venture Management LLC
614,095   Derivative/Non-derivative trans. at $0 per share. 0
06/22/2021 Versant Venture Management LLC
9,936,011   Derivative/Non-derivative trans. at $0 per share. 0
06/22/2021 FUJIFILM Holdings Corp.
3,974,404   Derivative/Non-derivative trans. at $0 per share. 0
06/22/2021 Eli Casdin
Director 		2,456,380   Derivative/Non-derivative trans. at $0 per share. 0
/news/latest/company/us/ipsc

MarketWatch News on IPSC

  1. Chardan Research initiates coverage of Century Therapeutics with a buy rating and $19 price target

    11:28 a.m. Dec. 27, 2022

  2. Century Therapeutics started at overweight with $40 stock price target at J.P. Morgan

    7:15 a.m. July 13, 2021

    - Tomi Kilgore

  3. Peter Thiel's Atai Life Sciences and 5 Other Companies List Shares

    5:19 p.m. June 18, 2021

    - Barron's Online

  6. Century Therapeutics sets IPO terms; to offer 10.6 mln shares priced at $18 to $20 each

    6:21 a.m. June 14, 2021

    - Ciara Linnane

/news/nonmarketwatch/company/us/ipsc

Other News on IPSC

  2. 10-Q: CENTURY THERAPEUTICS, INC.

    8:34 a.m. Nov. 10, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  4. Athersys: Is Big Pharma Sleeping At The Wheel?

    11:43 p.m. Oct. 5, 2022

    - Seeking Alpha

  5. Century Therapeutics (IPSC) Investor Presentation - Slideshow

    9:41 a.m. Sept. 14, 2022

    - Seeking Alpha

  8. 10-Q: CENTURY THERAPEUTICS, INC.

    7:34 a.m. Aug. 11, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  10. Century Therapeutics (IPSC) Investor Presentation - Slideshow

    8:42 a.m. July 1, 2022

    - Seeking Alpha

  12. 10-Q: CENTURY THERAPEUTICS, INC.

    7:37 a.m. May 16, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  13. Company Corporate Overview Presentation Apr 2022

    5:50 p.m. April 29, 2022

    - Seeking Alpha

  16. What's Behind Bristol Myers Squibb's Latest Partnership?

    12:29 p.m. Jan. 22, 2022

    - Motley Fool

  21. Loading more headlines...

At a Glance

Century Therapeutics, Inc.

3675 Market Street

Philadelphia, Pennsylvania 19104

Phone

1 2678175790

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2023

View SEC Filings

Revenue

$5.20M

Net Income

$-130.93M

Employees

163.00

Annual Report for IPSC

/news/pressrelease/company/us/ipsc

Press Releases on IPSC

  1. Century Therapeutics to Present at the AACR Annual Meeting 2023

    4:01 p.m. March 15, 2023

    - GlobeNewswire

  21. Loading more headlines...
Link to MarketWatch's Slice.